Deep Reasoning Ai, Inc. appears in the linked FDA record as the applicant for a single Traditional 510(k), K262134, for a device named NeuroDR. The submission was received on June 25, 2026, and decided on October 7, 2026, with a Substantially Equivalent decision under 21 CFR 892.2050, product code QIH, in the Radiology panel. The FDA record lists the device as Automated Radiological Image Processing Software, Class II. The company's own site describes NeuroDR as software that processes head and neck CT angiography scans into 3D anatomical models, vessel centerlines and reconstructed images. [1][2][3][4]

The documented filing and its scope

K262134 was submitted as a Traditional 510(k) with no third-party review and no authorized predetermined change control plan, according to the FDA premarket notification record. The regulation is 21 CFR 892.2050, Medical Image Management and Processing System, Class II, product code QIH, reviewed by the Radiology panel. The decision description is Substantially Equivalent, and the submission included a summary rather than only a statement. [2][4][9]

The FDA correspondence in the file is addressed to Cooper Molloy, identified as a regulatory consultant at Innolitics, LLC, at an Austin, Texas address. That address belongs to the correspondent, not to the applicant, and the record does not establish a company headquarters. The applicant address in the 510(k) database entry is in Sarasota, Florida; it is a filing address and is not treated here as a verified corporate headquarters. [1][2][4]

What NeuroDR does, as described

The company's product page states that NeuroDR processes head and neck CT angiography scans to create detailed 3D anatomical models, vessel centerlines and reconstructed images, with visualization of arterial anatomy from the aortic arch to the vertex, including anterior and posterior circulations. The company homepage describes transforming medical images into patient-specific 3D anatomical models using AI based on anatomical knowledge, and lists models spanning blood vessels, the spine, hips, skull and skeleton. Those broader model categories are company descriptions; only NeuroDR is tied to the linked FDA clearance. [3][6]

A 3DR Labs announcement, published by that company, describes NeuroDR as fully automated, AI-driven Software as a Medical Device developed in partnership with Deep Reasoning AI, and states that it produces 3D neurovascular centerlining and reconstructions in minutes. The same announcement attributes to the technology deep learning with reasoning based on anatomical knowledge, intended to remain stable in the presence of metal implants, imaging artifacts and anatomical variations. These are the announcing company's characterizations, not independently verified performance results. [8]

Evidence in the submission and company announcements

The FDA correspondence references test datasets that were independent from the data used during model training, and describes assessment of distributions of age, sex and geographic location along with incorporated data with potential confounders such as abnormalities, anomalies and pathologies. The supplied excerpt does not report numerical results, so no accuracy or performance figures are stated here. [2]

Deep Reasoning AI's news page, dated October 27, 2026, announces 510(k) clearance K262134 for NeuroDR in collaboration with Innolitics. The same page references an NIH project, 1R41DE034646-01, with named principal investigators, and earlier research on deep reasoning networks. Those items are company announcements and do not establish ownership, funding outcomes or clinical benefit. [7]

How to read the collection

The supplied portfolio snapshot, retrieved November 20, 2026, contains one linked record, a 510(k) with a Substantially Equivalent decision; the record sample contains that same single entry. The snapshot's decision counts and sample decision counts therefore both show one SESE decision. This is a count of supplied filings at a point in time, not a measure of total portfolio, sales or safety performance, and no recalls appear in the supplied sample. [1][4]

The relationship between Deep Reasoning Ai, Inc. and 3DR Labs is described by 3DR Labs as a partnership; the public documents do not identify a parent company, subsidiary structure or ownership stake. Statements about commercial availability, customers or clinical use beyond the cleared indication are not established by these documents. [8][9]